Assessing the Value of New Treatments for Anemia in Chronic Kidney Disease, featuring a Patient Perspective

Assessing the Value of New Treatments for Anemia in Chronic Kidney Disease, featuring a Patient Perspective

Faculty Presenters

Desola Davis, PharmD, BCPS, BCACP
Drug Use Management Clinical Pharmacy Specialist
Kaiser Permanente Georgia
Atlanta, Georgia
 
Program Description
Anemia is a common complication of chronic kidney disease (CKD), with symptoms including fatigue, weakness, headaches, dizziness, and difficulty breathing or shortness of breath. Current standards of care for anemia related to CKD are iron supplementation, blood transfusions, or erythropoiesis-stimulating agents (ESAs). Patients with CKD have several comorbid conditions, with cardiovascular disease being the most common, which complicates treatment decisions in some patients as treatment with ESAs carries risk of cardiovascular toxicity. Novel treatment mechanisms target hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase inhibitors to treat anemia in patients with CKD whether they are dialysis-dependent or not as well as those who are at risk for cardiovascular events. As new treatments such as these enter the treatment paradigm of CKD-related anemia, managed care professionals must understand potential complications and the role of these new agents in lowering disease burden for patients and healthcare resource utilization for payers. This activity includes the perspective of a caregiver and patient with CKD-related anemia who will share their experience with this disease highlighting the burden of disease exacerbations and how this condition has affected their quality of life.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 29, 2021
Expiration date: June 29, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Determine the relationship of inflammation and anemia, as well as the role of hepcidin and other pathophysiology in chronic kidney disease (CKD)-related anemia
• Identify the current standards of care and current challenges treating anemia in CKD
• Apply hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase inhibitors to treat anemia in dialysis-dependent and non–dialysis-dependent CKD
• Examine how new treatments can benefit current healthcare burden and quality of life for patients who have anemia in CKD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-169-H01-P. The activity is available for CE credit through April 29, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Desola Davis, PharmD, BCPS, BCACP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms